Issue Date: January 25, 2016
Pharma Contract Manufacturers Pursue Quantity And Quality
In 2004, drug giant Pfizer ran 80 manufacturing sites. By 2014, as its product volumes dropped and cost-cutting ensued, that number had fallen to 55, even after a megamerger with Wyeth. With its 2015 acquisition of Hospira and ongoing deal for Allergan, Pfizer is likely to consolidate further. And it isn’t alone.
After two banner years for mergers and acquisitions (M&A), pharma industry outsourcing to contract manufacturing organizations is increasing. CMOs are responding by investing . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society